>>AUSTIN, Texas, Feb. 21 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that it has received notification from the U.S. Patent and Trademark Office that the name ADVEXIN® is now a registered trademark in connection with Introgen's novel gene based drug for cancer. Introgen notified the Federal Food and Drug Administration (FDA) of the mark. The mark is registered in the United States, the European Community, and numerous other countries. The gene therapeutic ADVEXIN® is currently the subject of two randomized and controlled Phase 3 clinical trials for the treatment of head and neck cancer as well as numerous other clinical studies for a variety of solid tumors such as lung, brain, prostate, breast and bladder cancers.
Max W. Talbott, Ph.D., Introgen's senior vice president of worldwide commercial development said, ``After almost twenty clinical studies, the product development phase of Adenoviral p53 ADVEXIN® is nearing completion. Introgen is now implementing pre-marketing strategies in preparation for the approval of this revolutionary cancer therapeutic.''
Introgen is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases. Introgen's product candidates engage precise molecular targets to produce a highly specific therapeutic effect. By selectively killing cancer cells and harnessing natural protection mechanisms, Introgen's product candidates may be less toxic than conventional treatments. Introgen specializes in combining appropriate gene delivery systems and therapeutic genes to make its gene-based drugs. Introgen is currently conducting two controlled, randomized Phase 3 clinical trials with its lead product, INGN 201, ADVEXIN®, for the treatment of head and neck cancer. Introgen's gene therapeutics have been used in approximately twenty clinical trials worldwide either alone or in combination with conventional treatments such as chemotherapy, surgery and radiotherapy. Introgen is also conducting a Phase 2 clinical trial for INGN 201, ADVEXIN®, in lung cancer and Phase 1 trials for INGN 201, ADVEXIN®, in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer. New applications using the human immune system with INGN 201, ADVEXIN®, are being explored. Introgen's second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase 1 clinical development.<<
snip
Cheers, Tuck |
